Biovica International
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202530.6.2025 23:40:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2025 of $37,507,184 Total cash as at April 30, 2025 of $2,475,945 Working capital deficiency as at April 30, 2025 of $527,130 Shareholder's equity as at April 30, 2025 of $33,668,042 During the quarter, the Company incurred $584,284 in cost for exploration activities at the Thunder Bay North project. The team performed drilling and follow-up geophysics activities at the Current Deposit, that were focused on expanding the high-grade ballrooms in the Lower Current and Bridge zones. The results of this program were critical in aiding the Company towards developing a revised high-grade
Karbon-X Acquires ALLCOT, Expanding Global Climate Solutions Platform30.6.2025 15:00:00 CEST | Press release
The acquisition unites climate policy expertise and emissions strategy with digital infrastructure and delivery at scale - accelerating trusted, measurable climate action worldwide. CALGARY, AB / ACCESS Newswire / June 30, 2025 / Karbon-X (OTCQX:KARX), an end-to-end climate solutions company, today announced the acquisition of ALLCOT, a global advisory firm with a legacy of supporting climate policy, carbon markets, and high-integrity project development. This acquisition brings together two complementary forces under one shared mission: to scale science-backed, verifiable climate solutions across industries and regions. Karbon-X's leadership in emissions tracking, verified portfolios, and climate strategy combined with Allcot's legacy of policy guidance, project credibility, and regional expertise form a unified climate solutions provider with end-to-end capabilities across both voluntary and compliance markets. "This is about unlocking scale with integrity," said Chad Clovis, CEO of
Eagle Football Holdings supports Leadership Changes at Olympique Lyonnais30.6.2025 09:30:00 CEST | Press release
PALM BEACH GARDENS, FL / ACCESS Newswire / June 30, 2025 / Eagle Football Holdings Limited today confirmed its support of leadership changes which shall occur at its subsidiary Eagle Football Group (France) and Olympique Lyonnais. John Textor, Chairman and majority owner of Eagle Football Holdings, acting in his capacity as the sole director, and on behalf of the sole shareholder, of Olympique Lyonnais, today appointed Michael Gerlinger to the position of Director General (CEO), and Michele Kang to the position of Chair and President. Mr. Textor has resigned from his leadership positions at Olympique Lyonnais, in favor of the appointment of Ms. Kang and Mr. Gerlinger. Michele Kang, who is also a leading shareholder of Eagle Football Holdings, has served on the OL board since 2023, has been appointed Chair and President. She will take an active role in supporting OL's executive management, including spearheading the club's appeal process with the DNCG. Michael Gerlinger, currently Chief
CEVA Joins Windrose To Test Long-Haul EV Trucking in China27.6.2025 19:00:00 CEST | Press release
ANTWERP, BELGIUM / ACCESS Newswire / June 27, 2025 / CEVA Logistics in Greater China is coming together with Windrose, leading heavy-duty electric truck provider, to conduct a feasibility study for the deployment of long-haul electric vehicle (EV) trucking in China. This collaboration marks a significant step forward in CEVA's commitment to sustainability and its pioneering efforts to lead the sustainable development of the logistics industry. Under this partnership, CEVA and Windrose have successfully conducted trials of long-haul electric trucking, including a round-trip journey from Greater Bay Area in Guangdong to Pingxiang, Guangxi, at the China-Vietnam border, and a 5,000-kilometer journey from Shenzhen to Alashankou, at the China-Kazakhstan border. These pilot runs resulted in a remarkable carbon emissions reduction of approximately 55% on average (WTW) per GLEC framework. Based on these successes, CEVA and Windrose will continue to conduct trial runs within China to further exp
GA-ASI Announces Investment in Dutch Technology Innovator Arceon26.6.2025 19:00:00 CEST | Press release
Selection Follows Successful Pitch During Blue Magic Netherlands Event SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 26, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) announces an investment in another Dutch business, Arceon, following the inaugural Blue Magic Netherlands (BMN) event held in November 2024. GA-ASI is a global leader in unmanned aircraft systems and related mission systems. GA-ASI selected Arceon following a compelling pitch they made during the BMN event and after detailed business and technology discussions with GA-ASI and GA's affiliates, General Atomics Energy and General Atomics Electromagnetic Systems. Arceon joins Emergent Swarm Solutions and Saluqi Motors as companies receiving investment from GA-ASI following the BMN event. Arceon is revolutionizing high-performance ceramic composites through their innovative, fast, scalable, and cost-effective melt infiltration process. Their cutting-edge Carbeon carbon-ceramic components - engineered for applicat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom